Chemours recalibrates 2026 to a phase of digestion and AI-driven pivot

When Chemours reported its second quarter, the headline was a classic “beat and lower” — adjusted EBITDA exceeded expectations, but management slashed the full-year outlook to $775–825 million from a prior mid-point of roughly $850 million. The culprit is a familiar one: the thermal and specialized solutions (TSS) segment, which is suffering from a post-transition overhang in the U.S. stationary aftermarket. What makes this quarter notable is not the forecast cut, but the company’s aggressive pivot toward higher-value, AI-adjacent markets — and its explicit signal that portfolio change is now on the table.

Result beats, but the path forward narrows

Chemours delivered an operating income of -$22 million for the quarter, but adjusted EBITDA exceeded consensus on disciplined cost control and TT pricing. The miss was net sales, which came in slightly below expectations. As CEO Denise Dignam explained, the aftermarket for Opteon refrigerants is “working through elevated inventory levels” — a hangover from the 2025 AIM Act transition, when Chemours front-loaded distributions to support new equipment installations. The forward guidance embeds a sharp sequential decline in TSS sales (mid-teens to 20% down in Q3) and a stepping down of TSS margin to the high-20s, a far cry from the 30%+ level long touted by the company. Indeed, just a quarter ago, Dignam had said, “We always talk about the TSS business to be around the 30% margin or higher.” Now, the near-term mix is punitive, and the company is asking investors to look through the noise to 2027 restocking.

I want to be clear; no portfolio action is off the table where we see an opportunity to unlock a step change in value creation for our shareholders.

TSS: digestion now, growth later?

The market has punished the stock hard — data centers and data center themes are now embedded in Chemours’ earnings, but they cannot offset a cyclical refrigerant slump. During Q&A, CFO Shane Hostetter acknowledged that the aftermarket is oversized right now and that the third quarter will see a “less favorable mix from lower Opteon aftermarket sales.” He was clear that the margin softness is a mix issue, not a structural change: “I still stand behind that this business is a 30-plus margin business.” But investors have heard this before. In the prior call, Dignam noted, “we still expect year-over-year growth in Opteon and TSS,” a promise now broken by the reality of channel destocking. In this context, the short-term pain is not without compensation: Chemours is leaning into liquid cooling, and it's a theme that’s gaining traction. The company announced nominal sales of its 2-phase liquid cooling fluid and cited a 70% year-over-year increase in customer trials. As Dignam put it, “we’ve recorded nominal sales of 2-phase liquid cooling products for sampling across 2-phase applications with several customers.”

The AI flywheel within Chemours

The bigger story is the strategic reinforcement of Performance Solutions and its tie to AI infrastructure. Within APM, Performance Solutions net sales grew 8% year-over-year, driven by semiconductor and data center demand. More than 40% of that portfolio now feeds AI/advanced electronics end markets, and management explicitly says this is where future EBITDA upside lies. Liquid cooling is the next leg — and liquid cooling is appearing in the global trajectory as well, with high-volume mentions around “data center design” and “kilowatts per rack.” Chemours is positioning itself as a fluoropolymer and fluid supplier to the AI compute buildout, but it remains early: sales into these high-growth markets are still a “high single-digit percentage” of total TSS and APM sales. As Dignam said, “anything related to liquid cooling data centers will be on top of that, and it’s part of the robust growth that we see.”

Financial tightening and optionality

The balance sheet also frames this quarter’s actions. Chemours repaid $270 million of its 2028 euro term loan, and management reiterated its intention to get net leverage to around 3.8x by year-end, down from a net debt of $3.5 billion at the most recent filing. That deleveraging — combined with EPA and West Virginia settlements — is meant to “derisk” the balance sheet and create strategic flexibility. The company is signaling that no portfolio path is off the table: from product-line divestments to strategic partnerships, everything is being considered. Given the depressed valuation (price-to-revenue of ~0.6x and a stock down ~43% from its May peak), the market is essentially pricing in neither the refrigerant recovery nor the AI pivot. Chemours has a credible long-term story, but it is tied to execution in an unforgiving patch.